Ries M, Kim H J, Zalewski C K, Mastroianni M A, Moore D F, Brady R O, Dambrosia J M, Schiffmann R, Brewer C C
Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-1260, USA.
Brain. 2007 Jan;130(Pt 1):143-50. doi: 10.1093/brain/awl310. Epub 2006 Nov 14.
Fabry disease, OMIM 301500, is a progressive multisystem storage disorder due to the deficiency of alpha-galactosidase A (GALA). Neurological and vascular manifestations of this disorder with regard to hearing loss have not been analysed quantitatively in large cohorts. We conducted a retrospective cross sectional analysis of hearing loss in 109 male and female patients with Fabry disease who were referred to and seen at the Clinical Center of the National Institutes of Health, Bethesda, MD, USA on natural history and enzyme replacement study protocols. There were 85 males aged 6-58 years (mean 31 years, SD 13) and 24 females aged 22-72 years (mean 42 years, SD 12). All patients underwent a comprehensive audiological evaluation. In addition, cerebral white matter lesions, peripheral neuropathy, and kidney function were quantitatively assessed. HL(95), defined as a hearing threshold above the 95th percentile for age and gender matched normal controls, was present in 56% [95% CI (42.2-67.2)] of the males. Prevalence of HL(95) was lower in the group of patients with residual GALA enzyme activity compared with those without detectable activity (33% versus 63%) HL(95) was present in the low-, mid- and high-frequency ranges for all ages. Male patients with HL(95) had a higher microvascular cerebral white matter lesion load [1.4, interquartile range (IQR) 0-30.1 +/- versus 0, IQR 0-0], more pronounced cold perception deficit [19.4 +/- 5.5 versus 13.5 +/- 5.5 of just noticeable difference (JND) units] and lower kidney function [creatinine: 1.6 +/- 1.2 versus 0.77 +/- 0.2 mg/dl; blood urea nitrogen (BUN): 20.1 +/- 14.1 versus 10.3 +/- 3.28 mg/dl] than those without HL(95) (P < 0.001). Of the females, 38% had HL(95). There was no significant association with cold perception deficit, creatinine or BUN in the females. Word recognition and acoustic reflexes analyses suggested a predominant cochlear involvement. We conclude that hearing loss involving all frequency regions significantly contributes to morbidity in patients with Fabry disease. Our quantitative analysis suggests a correlation of neuropathic and vascular damage with hearing loss in the males. Residual GALA activity appears to have a protective effect against hearing loss.
法布里病(OMIM 301500)是一种由于α-半乳糖苷酶A(GALA)缺乏引起的进行性多系统贮积症。在大型队列研究中,尚未对该疾病与听力损失相关的神经和血管表现进行定量分析。我们对109例法布里病患者的听力损失情况进行了回顾性横断面分析,这些患者因自然病史和酶替代研究方案被转诊至美国马里兰州贝塞斯达市国立卫生研究院临床中心并接受诊治。其中有85名男性,年龄在6至58岁之间(平均31岁,标准差13),24名女性,年龄在22至72岁之间(平均42岁,标准差12)。所有患者均接受了全面的听力学评估。此外,还对脑白质病变、周围神经病变和肾功能进行了定量评估。HL(95)定义为年龄和性别匹配的正常对照者第95百分位数以上的听力阈值,在56% [95%可信区间(42.2 - 67.2)]的男性中存在。与无GALA酶活性可检测的患者相比,残余GALA酶活性患者组中HL(95)的患病率较低(33%对63%)。HL(95)在所有年龄段的低频、中频和高频范围内均有出现。患有HL(95)的男性患者微血管脑白质病变负荷更高[1.4,四分位数间距(IQR)0 - 30.1 ± 对0,IQR 0 - 0],冷觉缺陷更明显[19.4 ± 5.5对13.5 ± 5.5的最小可觉差(JND)单位],肾功能更低[肌酐:1.6 ± 1.2对0.77 ± 0.2mg/dl;血尿素氮(BUN):20.1 ± 14.1对10.3 ± 3.28mg/dl],与无HL(95)的男性患者相比(P < 0.001)。在女性患者中,38%有HL(95)。女性患者中HL(95)与冷觉缺陷、肌酐或BUN之间无显著关联。单词识别和听觉反射分析提示主要为耳蜗受累。我们得出结论,涉及所有频率区域的听力损失对法布里病患者的发病率有显著影响。我们的定量分析表明男性患者的神经病变和血管损伤与听力损失相关。残余GALA活性似乎对听力损失有保护作用。